Arcus biosciences, inc. (RCUS)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flow from operating activities
Net loss

-94,793

-84,710

-80,407

-68,866

-54,310

-49,594

-50,509

-62,820

-58,836

-53,082

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

10,769

8,981

7,598

5,906

4,892

3,874

2,975

2,064

1,079

495

0

0

0

Depreciation and amortization

3,467

3,578

3,669

3,757

3,789

3,664

3,483

3,241

2,954

2,612

0

0

0

Share of loss from equity method investee

-1,253

-1,202

-1,525

-1,353

-1,091

-886

-719

-652

-572

-416

0

0

0

Gain on deemed sale from equity method investee

482

0

0

0

0

-

-

-

-

-

-

-

-

Amortization of premiums on investments

2,139

2,638

2,948

3,332

2,499

1,752

0

0

0

-

-

-

-

Other non-operating income

-

-

-

-

-

177

199

222

127

98

0

0

0

Changes in operating assets and liabilities:
Receivable from collaboration partners

0

-

-

-

0

-

-

-

-

-

-

-

-

Amounts owed by a related party

0

-83

-114

-131

-54

58

79

172

54

-380

0

0

0

Prepaid expenses and other current assets

4,927

1,982

1,894

1,723

1,246

1,180

651

794

1,348

751

0

0

0

Other long-term assets

649

588

59

115

110

80

0

0

0

-

-

-

-

Accounts payable

-99

1,726

866

-1,982

-280

-69

1,010

2,690

2,119

-267

0

0

0

Accrued liabilities

2,541

3,499

2,995

11,214

4,693

3,497

5,112

2,573

2,461

1,582

0

0

0

Other current liabilities

43

57

52

52

48

43

-131

-136

-137

-136

0

0

0

Deferred revenue

-2,000

-2,000

-1,812

-1,353

-853

-353

0

0

0

-

-

-

-

Deferred rent

-540

-538

-521

-506

-510

-468

343

301

277

209

0

0

0

Net cash used in operating activities

-87,900

-73,462

-71,098

-55,464

-46,588

-42,996

-20,302

-32,771

-28,709

-25,059

0

0

0

Cash flow from investing activities
Purchases of short-term and long-term investments

184,233

247,755

219,730

294,718

292,875

261,552

281,179

156,061

116,560

96,830

0

0

0

Proceeds from maturities of short-term and long-term investments

270,728

308,892

295,544

257,408

213,522

151,855

126,941

97,603

71,920

53,273

0

0

0

Purchases of property and equipment

1,506

1,925

1,987

2,564

3,317

3,743

3,779

3,491

4,429

5,514

0

0

0

Net cash provided by investing activities

84,989

59,212

73,827

-39,874

-82,670

-113,440

-158,017

-61,949

-49,069

-49,071

0

0

0

Cash flow from financing activities
Proceeds from initial public offering, net of issuance costs

-

-

-

-

-

125,111

0

0

0

-

-

-

-

Proceeds from issuance of common stock

0

-

-

-

0

-

-

-

-

-

-

-

-

Repurchase of unvested shares of stock

0

-

0

0

0

-

0

0

0

-

-

-

-

Proceeds from issuance of common stock upon exercise of stock options, net of repurchases

-

-

-

-

-

-

3,422

3,615

4,167

892

0

0

0

Payment of preferred stock issuance costs

-

-

-

-

-

135

0

0

0

-

-

-

-

Net cash provided by (used in) financing activities

1,738

1,123

1,374

1,408

-359

129,074

234,902

235,098

236,795

107,396

0

0

0

Net increase (decrease) in cash and cash equivalents

-1,173

-13,127

4,103

-93,930

-129,617

-27,362

56,583

140,378

159,017

33,266

0

0

0

Non-cash investing and financing activities:
Unpaid financing cost included in accounts payable and accrued liabilities

-

-

-

-

-

-

-

-

0

-

-

-

-

Unpaid portion of property and equipment purchases included in accounts payable and accrued liabilities

-292

12

66

-823

-179

136

418

850

-67

338

0

0

0

Vesting of early exercised stock options and restricted stock

976

1,029

1,078

1,162

1,271

1,276

1,077

796

491

235

0

0

0